Tag Archives: Women’s

Weekly Roundup for MARCH 22, 2019: Recent Publications in Women’s Mental Health

The excitement over the FDA approval of brexanolone (to be marketed as Zulresso) is a good place to start this week’s roundup.  Brexanolone is a derivative of the neurosteroid allopregnanolone, and, while Zulpresso was approved specifically for the treatment of postpartum depression, there is considerable research to indicate that the modulation of neurosteroid systems may… Read More »

Weekly Roundup for MARCH 1, 2019: Recent Publications in Women’s Mental Health

This week there are a series of articles related to the recommendations issued by the US Preventive Services Task Force (USPSTF) several weeks ago, stating that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and recommends that women at increased risk for perinatal depression should be referred… Read More »